Xin Li

Summary

Affiliation: University of Arkansas for Medical Sciences
Country: USA

Publications

  1. ncbi Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth
    Xin Li
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    J Bone Miner Res 27:1635-48. 2012
  2. ncbi Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability
    Xin Li
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Cancer Lett 284:175-81. 2009
  3. ncbi Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone
    Xin Li
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Stem Cells 29:263-73. 2011
  4. ncbi Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone
    Angela Pennisi
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America
    PLoS ONE 5:e15233. 2010
  5. ncbi Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease
    Angela Pennisi
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 145:775-87. 2009
  6. ncbi Role of decorin in the antimyeloma effects of osteoblasts
    Xin Li
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 112:159-68. 2008
  7. ncbi The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth
    Angela Pennisi
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 114:1803-12. 2009
  8. ncbi The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo
    Angela Pennisi
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Am J Hematol 84:6-14. 2009
  9. ncbi Repression of multiple myeloma growth and preservation of bone with combined radiotherapy and anti-angiogenic agent
    Dan Jia
    Department of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, AR72205, USA
    Radiat Res 173:809-17. 2010
  10. ncbi Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
    Frits van Rhee
    University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, Little Rock AR 72205, USA
    Mol Cancer Ther 8:2616-24. 2009

Detail Information

Publications11

  1. ncbi Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth
    Xin Li
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    J Bone Miner Res 27:1635-48. 2012
    ....
  2. ncbi Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability
    Xin Li
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Cancer Lett 284:175-81. 2009
    ..4HPR is a potential anti-MM agent, affecting MM cells and MM-induced bone disease and angiogenesis...
  3. ncbi Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone
    Xin Li
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Stem Cells 29:263-73. 2011
    ..This study suggests that altering the bone marrow microenvironment with PDAC cytotherapy attenuates growth of myeloma and that PDAC cytotherapy is a promising therapeutic approach for myeloma osteolysis...
  4. ncbi Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone
    Angela Pennisi
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America
    PLoS ONE 5:e15233. 2010
    ..Current management of myeloma bone disease is limited to the use of antiresorptive agents such as bisphosphonates...
  5. ncbi Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease
    Angela Pennisi
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 145:775-87. 2009
    ..These data demonstrated that DASH proteases are involved in myeloma bone disease and tumour growth...
  6. ncbi Role of decorin in the antimyeloma effects of osteoblasts
    Xin Li
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 112:159-68. 2008
    ....
  7. ncbi The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth
    Angela Pennisi
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 114:1803-12. 2009
    ..Myeloma cells expressed low to undetectable ephrinB2 and EphB4 and did not respond to the chimeric proteins. The ephrinB2/EphB4 axis is dysregulated in MM, and its activation by EphB4-Fc inhibits myeloma growth and bone disease...
  8. ncbi The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo
    Angela Pennisi
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Am J Hematol 84:6-14. 2009
    ....
  9. ncbi Repression of multiple myeloma growth and preservation of bone with combined radiotherapy and anti-angiogenic agent
    Dan Jia
    Department of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, AR72205, USA
    Radiat Res 173:809-17. 2010
    ..These results suggest that radiotherapy, when primed by anti-angiogenic agents, may be a potent therapy for focal multiple myeloma...
  10. ncbi Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
    Frits van Rhee
    University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, Little Rock AR 72205, USA
    Mol Cancer Ther 8:2616-24. 2009
    ....
  11. ncbi Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines
    Xin Li
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 138:802-11. 2007
    ..These myeloma cell lines and the procedures used for their establishment provide essential tools for studying myeloma biology and therapy...